Patients lacking glycemic control place more burdens on health services with the use of medications.
DM spending in the world is high, and Brazilian studies of public spending caused by DM are scarce. To estimate the annual direct cost for the municipal health sphere, related to DM2 treatment, in patients with and without glycemic control. A cross-sectional study carried out in a city in the interior of Minas Gerais state, with patients with DM2, being municipal PHS users. Data were collected from the computerized system of the municipality and patient records, and analyzed using the IBM SPSS v.19 statistical package. The response variable was categorized into controlled A1c (≤7%) and uncontrolled A1c (>7%). Glycemic control in 56.6% of the patients was unsatisfactory; the mean cost of pharmacotherapy for DM2 was US$ 3.14 per year for patients in the control group and US$ 45.54 per year for uncontrolled patients. Patients with unsatisfactory glycemic control are more expensive for the municipal health system.